FPHAX Holdings Information

FPHAX is a mutual fund with a total of 59 individual holdings. The top holdings are Eli Lilly and Company stock at 24.47%, GSK plc at 7.92%, Merck & Co. at 6.37%, Viatris at 5.46%, and AstraZeneca at 4.98%.

Total Holdings

Top 10 Percentage

72.07%

Asset Class

Equity

Fund Category

Health

Assets

1.61B

Forward PE Ratio

n/a

Breakdown by Asset Class

Top 25 Holdings

No.	Symbol	Name	% Weight	Shares
1	LLY	Eli Lilly and Company	24.47%	345,601
2	GSK	GSK plc	7.92%	2,576,560
3	MRK	Merck & Co., Inc.	6.37%	704,636
4	VTRS	Viatris Inc.	5.46%	5,401,100
5	LON: AZN	AstraZeneca PLC	4.98%	501,350
6	EBR: UCB	UCB SA	4.96%	324,200
7	BMY	Bristol-Myers Squibb Company	4.61%	1,128,100
8	SWX: ROP	Roche Holding AG	4.57%	170,940
9	GILD	Gilead Sciences, Inc.	4.47%	499,200
10	ELAN	Elanco Animal Health Incorporated	4.26%	2,908,100
11	JAZZ	Jazz Pharmaceuticals plc	4.22%	274,800
12	LEGN	Legend Biotech Corporation	3.30%	2,591,700
13	MRNA	Moderna, Inc.	3.20%	372,300
14	RPRX	Royalty Pharma plc	2.60%	692,000
15	BNTX	BioNTech SE	1.71%	275,553
16	JNJ	Johnson & Johnson	0.96%	59,100
17	NTLA	Intellia Therapeutics, Inc.	0.91%	1,165,300
18	BEAM	Beam Therapeutics Inc.	0.90%	500,600
19	OCUL	Ocular Therapeutix, Inc.	0.86%	1,331,717
20	XENE	Xenon Pharmaceuticals Inc.	0.83%	226,000
21	AXSM	Axsome Therapeutics, Inc.	0.76%	62,700
22	n/a	Fidelity Cash Central Fund	0.65%	10,666,711
23	KYMR	Kymera Therapeutics, Inc.	0.61%	84,500
24	AMLX	Amylyx Pharmaceuticals, Inc.	0.53%	257,800
25	ELVN	Enliven Therapeutics, Inc.	0.51%	143,047

Showing 25 of 59 holdings

Subscribe to see the full list

Activate Now

As of Aug 31, 2026